glp-1 obesity drug news updates New research is challenging long-held assumptions about drugs in weight loss treatments. A different approach may be emerging.⁠ ⁠ Click the link in bio to read the full story The next phase of the

A study of nearly 1.1 million people found that semaglutide (the drug in Ozempic and Wegovy) was associated with a 40-70% lower risk of developing Alzheimer's compared to other diabetes medications

If a product has not been FDA-approved for a specific condition, it cannot be promoted as safe or effective for that condition

Our goal is to offer novel insights into the optimization of bone health management in the context of weight loss, guided by a translational medicine perspective.

Learn about the latest science behind GLP-1 weight loss drugs, the nutritional needs of GLP-1 users and what this means for future innovation in food and beverage.

While effective, these treatments require monitoring due to potential side effects, especially in non-diabetic patients.This therapeutic advancement represents a revolution in the management of metabolic diseases and obesity.Despite their efficacy in managing obesity and metabolic disorders, GLP-1 and GIP receptor agonists can cause side effects, which are a common reason for therapy discontinuation

New FDA regulations and legal actions are phasing out compounded GLP-1s, while companies introduce lower-priced, FDA-approved alternatives.